23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Women worldwide are more likely to develop breast cancer (BC) than any other type of cancer. The treatment of BC depends on the subtype and stage of the cancer, such as surgery, radiotherapy, chemotherapy, and immunotherapy. Although significant progress has been made in recent years, advanced or metastatic BC presents a poor prognosis, due to drug resistance and recurrences. During embryonic development, myeloid-derived suppressor cells (MDSCs) develop that suppress the immune system. By inhibiting anti-immune effects and promoting non-immune mechanisms such as tumor cell stemness, epithelial-mesenchymal transformation (EMT) and angiogenesis, MDSCs effectively promote tumor growth and metastasis. In various BC models, peripheral tissues, and tumor microenvironments (TME), MDSCs have been found to amplification. Clinical progression or poor prognosis are strongly associated with increased MDSCs. In this review, we describe the activation, recruitment, and differentiation of MDSCs production in BC, the involvement of MDSCs in BC progression, and the clinical characteristics of MDSCs as a potential BC therapy target.

          Related collections

          Most cited references153

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

          Myeloid-derived suppressor cells (MDSC) are a heterogeneous population expanded in cancer and other chronic inflammatory conditions. Here the authors identify the challenges and propose a set of minimal reporting guidelines for mouse and human MDSC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Coordinated regulation of myeloid cells by tumours.

            Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and are a collection of distinct cell populations with many diverse functions. The three groups of terminally differentiated myeloid cells - macrophages, dendritic cells and granulocytes - are essential for the normal function of both the innate and adaptive immune systems. Mounting evidence indicates that the tumour microenvironment alters myeloid cells and can convert them into potent immunosuppressive cells. Here, we consider myeloid cells as an intricately connected, complex, single system and we focus on how tumours manipulate the myeloid system to evade the host immune response.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

              High-dose ionizing irradiation (IR) results in direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both locally and distantly. Unfortunately, local relapses often occur following IR treatment, indicating that IR-induced responses are inadequate to maintain antitumor immunity. Therapeutic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T cell effector function when PD-L1 is expressed in chronically inflamed tissues and tumors. Here, we demonstrate that PD-L1 was upregulated in the tumor microenvironment after IR. Administration of anti-PD-L1 enhanced the efficacy of IR through a cytotoxic T cell-dependent mechanism. Concomitant with IR-mediated tumor regression, we observed that IR and anti-PD-L1 synergistically reduced the local accumulation of tumor-infiltrating myeloid-derived suppressor cells (MDSCs), which suppress T cells and alter the tumor immune microenvironment. Furthermore, activation of cytotoxic T cells with combination therapy mediated the reduction of MDSCs in tumors through the cytotoxic actions of TNF. Our data provide evidence for a close interaction between IR, T cells, and the PD-L1/PD-1 axis and establish a basis for the rational design of combination therapy with immune modulators and radiotherapy.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                03 July 2023
                2023
                : 14
                : 1199273
                Affiliations
                [1] 1 Department of Radiotherapy, Second Hospital of Jilin University , Changchun, China
                [2] 2 National Health Commission (NHC) Key Laboratory of Radiobiology, School of Public Health, Jilin University , Changchun, China
                Author notes

                Edited by: Robert Wesolowski, The Ohio State University, United States

                Reviewed by: Ik-Hwan Han, Kyung Hee University, Republic of Korea; Rodwell Mabaera, Dartmouth Hitchcock Medical Center, United States

                *Correspondence: Yanming Yang, yym180@ 123456163.com
                Article
                10.3389/fimmu.2023.1199273
                10350567
                37465670
                8792ac4d-fbac-4e09-ac70-b563a308c87f
                Copyright © 2023 Liu, Wang, Zhou and Yang

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 03 April 2023
                : 19 June 2023
                Page count
                Figures: 4, Tables: 2, Equations: 0, References: 154, Pages: 17, Words: 8468
                Funding
                This work was supported by Science and technology Development Plan of Jilin (20210402026GH); Key Laboratory of Metrology and calibration technology (JLKG2021001C004).
                Categories
                Immunology
                Review
                Custom metadata
                Cancer Immunity and Immunotherapy

                Immunology
                myeloid-derived suppressor cells,breast cancer,immunosuppression,immunotherapy,tumor microenvironments

                Comments

                Comment on this article